

Antimicrobial Resistance in Pathogens Causing Pediatrics Bloodstream Infections in a Saudi Hospital

M. A. Abo-Shadi^{1*}, A. A. Al-Johani² and A. A. Bahashwan³

¹*Microbiology and Immunology Dept., Faculty of Pharmacy, Al-Azhar University, Egypt*

²*Biology Department, Faculty of Science, Taibah University, KSA*

³*Laboratory of Madinah Maternity and Children's Hospital, KSA*

ABSTRACT

Background: Bloodstream infection (BSI) is one of the most common life-threatening conditions in hospitalized pediatrics especially if associated with resistant microbes.

Aims: To determine the incidence, predisposing factors, microbiological and antimicrobial resistance patterns in suspected BSI pediatric patients in a Saudi hospital.

Place and Duration of Study: Different wards of Madinah Maternity and Children's Hospital, Saudi Arabia, during one year period from July 1, 2009 to June 30, 2010.

Methodology: Blood cultures were performed to all cases (n= 11968) using Bactec 9240 instrument **Blood Culture Systems**. Microorganisms were identified by colony morphology, Gram stain and biochemical profiles. BD Phoenix™ was used in confirmation of identification of all BSI Gram-negative isolates. Antibiotic susceptibility pattern of isolates was further done by using disk diffusion method.

Results: 728 cases (6.1%) were diagnosed **with BSI after having a one positive blood culture**. The overall mortality rate was 11%. Gram-positive, Gram-negative and yeast accounted for 63.8%, 31.6% and 4.6% of the total isolates, respectively. Coagulase-negative staphylococci were the most prevalent Gram-positive isolates (44%); while *Serratia marcescens* and *Klebsiella pneumoniae* were the most common Gram-negatives. Gram-positive bacteria were mostly sensitive to cephalothin (82.3%) and vancomycin (72.2%), while Gram-negative bacteria were mostly sensitive to ciprofloxacin (93%), piperacillin/tazobactam (92.9%), and meropenem (89.8%).

Conclusion: The incidence rate of BSI is highest in ICU neonates. **Therefore**, special attention should be given to the quality of care **provided** for them to improve safety. There was appreciable resistance to commonly used antibiotics; and continued monitoring of antibiotic resistance is of great importance to ensure the proper use of antibiotics and to detect any increasing trends in resistance.

Keywords: Bloodstream infections; pediatrics; antimicrobial resistance; Saudi Arabia.

*Corresponding author: Email: m_a_shadi@hotmail.com

20 1. INTRODUCTION

21

22 Bloodstream infections (BSIs) are among the most common hospital-acquired infections in
23 pediatric patients, and are responsible for approximately 10% to 30% of the cases (Gray,
24 2004). Moreover, bacterial sepsis is the seventh leading cause of infant mortality for 2010 in
25 United States (Sherry et al., 2012).

26 Most of the literature concerning BSI is generated from adult patients that cannot be directly
27 extrapolated to children because of significant differences in age, underlying medical
28 conditions or type, and distribution of pathogens (Yogaraj et al., 2002).

29 BSI are a serious cause of morbidity and mortality worldwide. Emerging antimicrobial drug
30 resistance among bacterial pathogens causing BSI can limit therapeutic options and
31 complicate patient management (Pourakbari et al., 2012). Furthermore, rates of antimicrobial
32 resistance are increasing rapidly nowadays with patterns of large variations between
33 countries.

34 Bacteriological culture to isolate the offending pathogen and knowledge about sensitivity
35 pattern of the isolates remain the gold standard in the definitive microbiological diagnosis
36 and management of BSI.

37 Although some studies on the incidence and epidemiology of BSI in pediatric patients have
38 been conducted in Saudi Arabia, this data is lacking in Madinah Region. Thus, the aim of the
39 present study was to determine the incidence, predisposing factors, microbiological and
40 antimicrobial resistance patterns in pediatric patients suffering from BSI in different wards of
41 Madinah Maternity and Children's Hospital (MMCH); so that a guideline can be prepared for
42 empirical antibiotic therapy in the hospital.

43

44 2. MATERIALS AND METHODS

45

46 2.1 Study location and patients

47 The present retrospective study was conducted in MMCH, Madinah Munawarah city, located
48 in the western part of Saudi Arabia, during one year period from 1 July 2009 to 30 June
49 2010. The hospital has 500 beds, and provides primary, secondary and tertiary health care.
50 It is also the main referral hospital for Madinah region.

51 Clinical standards of practice in hospitals entail collecting blood for culture from patients
52 exhibiting clinical signs of infection (e.g., fever $>38^{\circ}\text{C}$). During the study period, 11968
53 suspected BSI pediatric patients (new born to 14 years) from different wards at MMCH,
54 Pediatric Intensive Care Unit (PICU), Neonatal Intensive Care Unit (NICU), Minimal Care
55 Unit (MCU), In-Patient Wards (IPWs) and Out-Patient Department (OPD), were included in
56 the study. Their mean age was 803.83 ± 1234.4 days with min. age of 2 days and max. of 14
57 years.

58 The clinical data collected from each patient medical record included: age, gender, hospital
59 ward, clinical diagnosis, length of hospitalization and risk factor including using intravenous
60 devices, urinary catheters, hemodialysis shunts, endotracheal tubes, ventilator support, and
61 previous antibiotic treatment given within the last month. Gestational age and birth body
62 weight was additional data collected for NICU dead patients. The date of death of patients
63 was compiled from the patient administrative system.

Criteria used for laboratory-confirmed BSI diagnosis should meet at least one of the following criteria: (1) At least one positive blood cultures for a known pathogen, which was not related to an infection at another site; (2) The patient experienced at least one of the following signs or symptoms: fever ($> 38^{\circ}\text{C}$), chills, hypotension (systolic blood pressure > 90 mmHg), and a common skin contaminant e.g., diphtheroids (*Corynebacterium* spp.), *Bacillus* spp., *Propionibacterium* spp., coagulase-negative staphylococci CoNS (including *Staph. epidermidis*), viridans group streptococci, *Aerococcus* spp., or *Micrococcus* spp. that was isolated from two or more blood cultures drawn on separate occasions (Liu et al., 2010). In neonates, in addition to the above criteria, the criteria included; toxic appearance, lethargy, hypotension, hypoventilation, hyperventilation or cyanosis.

An episode of BSI was defined as isolation of one or more recognised bacterial or fungal pathogens from one or more blood cultures. Only the first isolate per patient is counted, unless at least 14 days has passed without a positive blood culture with the same organism, after which an additional episode is recorded. All significant organisms were reported in a polymicrobial episode.

If a potential skin contaminant was isolated (e.g. CoNS, diphtheroid, etc), and the organism was isolated from two or more blood cultures drawn on separate occasions within 48 hours, the patient must have at least one of the following signs and symptoms within 24 hours of the blood culture being collected: fever ($>38^{\circ}\text{C}$), chills, rigors, hypotension (For patients aged >1 year); and fever ($>38^{\circ}\text{C}$ core), hypothermia ($<36^{\circ}\text{C}$ core), apnoea or bradycardia (For patients aged ≤ 1 year).

BSI was considered as community acquired if developed before or within 48 hours after admission (except for isolates with a long incubation period as *Salmonella typhi*) and was not maternally-acquired; and it was considered to be hospital acquired if it occurred more than 48 hours after hospital admission or within 48 hours of discharge and were in-direct relation to medical procedures undertaken in the hospital.

2.2 Isolation, identification and antibiotic susceptibility testing of microbial isolates from BSI cases

Blood samples for culture were obtained from pediatric patients by venipuncture after sterilization of the skin with 70% isopropyl alcohol or from umbilical catheters using aseptic techniques. Pediatric blood culture bottle (Bactec Peds plus/F 40-ml culture vial, aerobic resin) was inoculated aseptically with 1-3 ml of blood from each case in accordance with the manufacturer's instructions. The bottles were then incubated in the Bactec 9240 instrument (Becton Dickinson, USA) for at least 7 days.

Specimens from the positive bottles, were gram stained, sub-cultured on the following media: blood agar, chocolate agar, MacConkey's agar and Sabouraud dextrose agar. Chocolate agar and blood agar plates were incubated in a CO_2 incubator with 5% to 10% CO_2 for up to 48 hours while other culture plates were incubated aerobically overnight at 37°C .

Identification of blood culture isolates was based on colony morphology, test results of catalase, coagulase, oxidase, urease, germ tube, optochin, bacitracin and biochemical profiles using API tests (BioMérieux, France) specific for gram-negative organisms. BD PhoenixTM NMIC/ID panels were also used to confirm the identification of all BSI Gram-negative isolates.

Furthermore, antibiotic susceptibility testing was done according to National Committee for Clinical Laboratory Standards (NCCLS, 2005).

3. RESULTS

Positive blood cultures were reported for 728 out of 11968 (6.1%) and were diagnosed as BSI at MMCH during the one year study period.

Table 1 shows Demographic characteristics of the 728 confirmed BSI pediatric patients. The highest mean duration of hospital stay and mortality rate was reported from MCU (9 months). The highest number of BSI microbial isolates was reported from NICU (280 isolate), and OPD (278 isolate), which also had the highest number of patients (241 and 275 patient respectively).

Table 1. Demographic characteristics of the 728 confirmed BSI pediatric patients

Characteristics	NICU	PICU	MCU	IPWs	OPD	Total
No. of patients	241	138	6	68	275	728
Male	139	70	5	41	160	415
Female	102	68	1	27	115	313
Mean duration of hospital stay	37 days	28 days	9 months	15 days	0	
No. of microbial isolates	280	186	9	74	278	827
Patient deaths	45	30	4	1	0	80
Mortality rate	18.7% (45/241)	21.7% (30/138)	66.7% (4/6)	1.5% (1/68)	0 (0/275)	11% (80/728)

NICU= Neonatal Intensive Care Unit, PICU= Pediatric Intensive Care Unit, MCU= Minimal Care Unit,

IPWs= In-Patient Wards, OPD= Out-Patient Department.

With regard to the place of acquisition of infection, 63% of microbial isolates (521/827) were acquired in the hospital, as compared to 37% (No/total) acquired in the community.

A total of 827 microbial isolates were detected from 728 BSI pediatric patients. The number of microbial isolates was more than number of the total cases because some patients had multiple episodes of BSI with different organisms.

Most BSI cases 720 (98.9%) were monomicrobial, while 8 (1.1%) cases only were polymicrobial (i.e., two different organisms were isolated from each case from the same blood culture).

Gram-positive bacteria were the most common BSI causative agents in those pediatric patients. They were 528 (63.8%) of the total isolates, whilst 261 isolates (31.6%) were Gram-negative bacteria. Furthermore, *Candida* spp. (*C. albicans* and other *Candida* spp.) were the only fungal species isolated from 38 (4.6%) of the total BSI cases.

Coagulase-negative staphylococci (CoNS) were the most common pathogens accounting for 44% of the total isolates, followed by *Streptococcus* spp. (10.6%). *Serratia marcescens* (7.5%), *Klebsiella* spp. (5.8%) and *P. aeruginosa* (3.9%) were the most common Gram-negative isolated pathogens (Table 2).

Table 2. Distribution of the BSI microbial isolates in the different wards of MMCH

Microbial isolates	No. of isolates					Total (%)
	NICU	PICU	MCU	IPWs	OPD	
Gram-positive organisms (total)	150	74	4	58	242	528 (63.8)
CoNS	106	53	2	37	166	364
MRSA	22	3	1	5	0	31
MSSA	5	4	0	4	14	27
<i>Streptococcus</i> spp.	14	10	1	9	54	88
<i>Micrococcus</i> spp.	1	1	0	0	1	3
<i>Enterococcus</i> spp.	2	2	0	3	1	8
<i>Corynebacterium diphtheria</i>	0	0	0	0	4	4
<i>Bacillus</i> spp.	0	1	0	0	2	3
Gram-negative organisms (total)	112	95	5	14	35	261 (31.6)
<i>Klebsiella</i> spp.	26	11	1	2	8	48
<i>Pseudomonas aeruginosa</i>	25	3	1	0	3	32
<i>Enterobacter</i> spp.	9	18	0	3	4	34
<i>Acinetobacter</i> spp.	6	12	1	2	3	24
<i>E. coli</i>	11	4	0	2	3	20
<i>Salmonella</i> spp.	5	0	0	1	5	11
<i>Stenotrophomonas maltophilia</i>	4	4	1	0	0	9
<i>Chryseobacterium meningosepticum</i>	4	0	0	1	0	5
<i>Citrobacter</i> spp.	1	1	0	1	1	4
<i>Haemophilus influenzae</i>	1	2	0	0	2	5
<i>Moraxella</i> spp.	0	0	0	0	2	2
<i>Brucella</i> spp.	0	0	0	1	3	4
<i>Achromobacter</i> spp.	1	0	0	0	0	1
<i>Serratia marcescens</i>	19	40	1	1	1	62
Fungi (total)	18	17	0	2	1	38 (4.6)
<i>Candida albicans</i>	4	1	0	0	0	5
Non <i>Candida albicans</i>	14	16	0	2	1	33
Total no. of isolates	280	186	9	74	278	827

CoNS = Coagulase-negative staphylococci, MRSA = Methicillin-resistant *S. aureus*, MSSA = Methicillin-sensitive *S. aureus* NICU = Neonatal Intensive Care Unit, PICU = Pediatric Intensive Care Unit, MCU = Minimal Care Unit, IPWs = In-Patient Wards, OPD = Out-Patient Department.

Gram-positive bacteria showed a high level of sensitivity to cephalothin and vancomycin. Methicillin resistant *Staph. aureus* (MRSA) was resistant to all the tested antibiotics except vancomycin (Table 3).

Antibacterial resistance rate of BSI Gram-negative isolates is represented in Table 4. All *Candida albicans* isolated were susceptible to amphotericin B and fluconazole; while 21% of non *Candida albicans* were resistant to fluconazole and 18.4% were resistant to amphotericin B (Not shown in a table).

165 **Table 3. Antibacterial resistance rate of BSI Gram-positive isolates understudy (n=**
166 **521*)**

Antibiotic	CoNS n=364	MRSA n=31	MSSA n=27	<i>Streptococcus</i> n=88	<i>Enterococcus</i> n=8	<i>Micrococcus</i> n=3
PG (10 IU)	337 (92.6)	31 (100)	27 (100)	65 (73.4)	8 (100)	3 (100)
E (15 µg)	313 (86.3)	31 (100)	3 (10)	23 (26.1)	8 (100)	3 (100)
AP (10 µg)	332 (91.2)	31 (100)	27 (100)	58 (65.9)	8 (100)	3 (100)
KF (30 µg)	36 (9.9)	31 (100)	0 (0)	17 (19.3)	8 (100)	0 (0)
CD (2 µg)	154 (42.3)	30 (96.8)	3 (11.1)	29 (33)	6 (75)	0 (0)
TS (25 µg)	186 (51.1)	31 (100)	3 (11.1)	67 (76.1)	4 (50)	0 (0)
VA (30 µg)	96 (26.4)	25 (80.6)	5 (18.5)	19 (21.6)	0 (0)	0 (0)

167 *MRSA = methicillin-resistant S.aureus; MSSA = methicillin-sensitive S.aureus; PG = Penicillins G, E=*
168 *Erythromycin, AP = Ampicillin, KF = Cephalothin, CD = Clindamycin, TS = Cotrimoxazole, VA =*
169 *Vancomycin, * Seven isolates of Bacillus & corynebacterium spp. were not tested.*

Table 4. Antibacterial resistance rate of BSI Gram-negative isolates under study (n= 256*)

Antibacterial resistance rates No. (%)											
	<i>Klebsiella</i> n=48	<i>E. coli</i> n=20	<i>S. marcescens</i> n=62	<i>Enterobacter</i> n=34	<i>P. aeruginosa</i> n=32	<i>Salmonella</i> n=11	<i>Citrobacter</i> n=4	<i>Acinetobacter</i> n=24	<i>C. meningosepticum</i> n=5	<i>S. maltophilia</i> n=9	<i>Moraxella</i> n=2
Beta-lactams											
CTX,30 µg	17 (35.4)	2 (10)	0 (0)	4 (11.8)	32 (100)	0 (0)	2 (50)	6 (25)	5 (100)	9 (100)	0 (0)
CAZ,30 µg	17 (35.4)	2 (10)	3 (4.8)	5 (14.7)	2 (6.3)	7 (63.6)	2 (50)	6 (25)	5 (100)	6 (66.7)	0 (0)
CRO,30 µg	20 (43.3)	2 (10)	22 (35.5)	5 (14.7)	20 (62.5)	11 (100)	2 (50)	12 (50)	3 (6)	9 (100)	2 (100)
CPD,10 µg	18 (36.7)	2 (10)	13 (21)	3 (8.8)	32 (100)	7 (63.6)	2 (50)	18 (75)	5 (100)	9 (100)	0 (0)
KF,30 µg	27 (56.3)	14 (70)	62 (100)	31 (91.1)	32 (100)	11 (100)	2 (50)	24(100)	5 (100)	9 (100)	2 (100)
CXM,30 µg	16 (33.3)	2 (10)	62 (100)	34 (100)	32 (100)	7 (63.6)	2 (50)	18 (75)	5 (100)	9 (100)	0 (0)
FOX,30 µg	11 (22.9)	0 (0)	62 (100)	31 (91.1)	32 (100)	7 (63.6)	2 (50)	24(100)	5 (100)	9 (100)	2 (100)
FEP,30 µg	17 (35.4)	2 (10)	0 (0)	0 (0)	2 (6.3)	4 (36.4)	2 (50)	6 (25)	5 (100)	9 (100)	0 (0)
AMP,10µg	48 (100)	20 (100)	62 (100)	31 (91.1)	18 (100)	7 (63.6)	4 (100)	24 (100)	5 (100)	9 (100)	0 (0)
PIP,100 µg	27 (56.3)	16 (80)	3 (4.8)	0 (0)	2 (6.3)	7 (63.6)	2 (50)	18 (75)	5 (100)	9 (100)	0 (0)
ATM,30 µg	17 (35.4)	2 (10)	13 (21)	3 (8.8)	7 (21.9)	7 (63.6)	2 (50)	24(100)	5 (100)	9 (100)	0 (0)
IMI, 10 µg	0 (0)	0 (0)	0 (0)	0 (0)	18 (56.3)	0 (0)	0 (0)	6 (25)	5 (100)	9 (100)	0 (0)
MEM,10µg	0 (0)	0 (0)	2 (3.2)	0 (0)	4 (12.5)	0 (0)	0 (0)	6 (25)	5 (100)	9 (100)	0 (0)
β-lactams/β-lactamase inhibitors											
AUG,30 µg	27 (56.3)	4 (20)	62 (100)	28 (82.4)	32 (100)	0 (0)	2 (50)	24 (100)	5 (100)	9 (100)	0 (0)
TZP100/10	0 (0)	0 (0)	3 (4.8)	0 (0)	2 (6.3)	0 (0)	0 (0)	4 (25)	5 (100)	6 (66.7)	0 (0)
non β-lactams											
GM,10 µg	12 (25)	0 (0)	3 (4.8)	0 (0)	5 (15.6)	11 (100)	0 (0)	4 (25)	5 (100)	9 (100)	0 (0)
AK,30µg	2 (4.2)	0 (0)	3 (4.8)	0 (0)	5 (15.6)	11 (100)	0 (0)	4 (25)	5 (100)	9 (100)	0 (0)
CIP, 5 µg	3 (6.3)	0 (0)	0 (0)	0 (0)	5 (15.6)	0 (0)	0 (0)	4 (25)	0 (0)	6 (66.7)	0 (0)
TS, 25 µg	21 (43.8)	12 (60)	5 (8.1)	3 (8.8)	32 (100)	7 (63.6)	2 (50)	24 (100)	5 (100)	3 (33.3)	2 (100)

171 CTX = Cefotaxime, CAZ = Ceftazidime, CRO = Ceftriaxone, CPD = Cefpodoxime, KF = Cephalothin, CXM = Cefuroxime, FOX = Cefoxitin, FEP = Cefepime, AMP =
 172 Ampicillin, PIP = Piperacillin, ATM = Aztreonam, IMI = Imipenem, MEM = Meropenem, AUG = amoxicillin-clavulanic acid, TZP = Piperacillin/tazobactam, GM = Gentamicin,
 173 Ak = Amikacin, CIP = Ciprofloxacin, TS = cotrimoxazole, * Five isolates of *Brucella* & *Achromobacter* spp. were not tested.

174

175 DISCUSSION

176 BSI still carries high morbidity and mortality in hospitalized patients despite the availability of
177 current sophisticated therapeutic modalities (Blomberg et al., 2007).

178 In the present investigation, we analyzed clinical and microbiological characteristics of BSI
179 pediatric patients in a Saudi hospital (MMCH); and results showed that 6.1% (728/11968) of
180 pediatric patients had at least one episode of BSI. Previous studies from Saudi Arabia have
181 documented widely varying pediatric infection rates between individual institutions
182 depending on the age group and the hospital ward. The observed incidence of BSI in NICU
183 was 9% at King Khalid University Hospital, Riyadh (Haque et al., 1990), and 40.9% at Abha
184 general hospital (Mahfouz et al., 2010). In contrast to our finding, a higher positivity rate
185 (between 36-55%) in pediatric patients was reported (Mahapatra et al., 2002; Jain et al.,
186 2003).

187 In the current study, 415/728 (57%) of the confirmed BSI pediatric patients were males and
188 313 (43%) were females. Similar finding have been reported by Al-Zamil (2008) in Riyadh,
189 where 58.7% of the total 259 pediatric patients with bacteremia were males and 41.3% were
190 females.

191 Out of the total 11968 admitted pediatrics, 6558 (54.8%) were males and the rest were
192 females. Thus, the rate of BSI in males (6.3%, 415/6558) was higher than females (5.8%,
193 313/5410). This is in accordance to data of Meyer et al. (2007) in their investigation of a total
194 of 1699 patients in 20 hospitals, where male patients had a significantly higher risk of
195 acquiring BSI than female patients (p=0.002). This slight difference could be attributed to a
196 higher admission rate of males compared to females.

197 The overall hospital-acquired BSI (521 microbial isolates, 63%) were relatively higher than
198 the community-acquired. Different hospital-acquired BSI rates (90%, Babay et al., 2007;
199 43%, Elbashier et al., 1998; 53%, Laupland et al., 2009) were reported.
200

201 The assessment of the risk factors associated with BSI revealed that the duration of
202 hospitalization prior to the occurrence of BSI is an important factor especially for cases of
203 multidrug resistance nosocomial BSIs (Biedenbach et al., 2004). In the present study, the
204 highest duration of hospital stay in MMCH (9 months) and mortality rate (4/6 patients,
205 66.7%) (Table 1) were reported from the MCU, whereas some patients had polymicrobial
206 infections. MCU is used for hospice-type patients who are terminally ill or incurably ill. Most
207 of those patients were mechanically ventilated or under continuous use of intravascular and
208 central venous catheterization. Central venous catheterization was reported to be the most
209 common risk factor for BSI that extends the length of stay, increases the cost of
210 hospitalization; and attributed to 4-37% of mortality (Rosenthal et al., 2003; McLaughlin et
211 al., 2012).

212 Surprisingly, mortality rate was higher in PICU than NICU. This may explained by the higher
213 infection rate in PICU (186/138, 1.34) than NICU (280/241, 1.16). There is of course a
214 problem in infection control of this unit, and this problem is now in concern of the infection
215 control department of MMCH.

216 The overall mortality among our patients was (80/728, 11%) (Table 1). Similar mortality rates
217 were reported by other Saudi pediatric studies (Abou Elella et al., 2010; Elbashier et al.,
218 1998; Babay et al., 2007). The 11% mortality rate in the current study was higher than that
219 reported by Gray (2004) where, the overall mortality rate directly attributable to infection was

2.4%. In addition, the mortality rate in the NICU was 18.7% in our investigation, which is comparable to a study performed previously in four main hospitals in Makkah (13.4%) Asghar (2006). Recently, Ballot et al. (2012), reported a mortality rate of 6.3% in the early-onset sepsis and 19.6% in the late-onset sepsis groups.

Due to the diversity of clinical conditions and wards, it was not possible to attribute the cause of death to BSI in all our patients. As, mortality could be attributed to different factors such as the causative organisms, age, underlying diseases and ICU admission (Babay, 2007). The most commonly isolated organisms in our patients who died of BSI were CoNS, *Klebsiella* spp. and *Candida* spp. CoNS, *S. aureus* and *Enterococcus* spp. were the most leading to death reported in another study (Babay, 2007).

In this investigation, 33 cases (73%) were preterm among neonates deaths. Premature neonates are at especially high risk of infection because of their lack of protective maternal antibodies, underdeveloped innate immunity and their fragile, easily damaged skin. However, while the newborn intrinsically faces an increased risk of infection, failures at critical points in the system of care can greatly increase this risk (Mahfouz et al., 2010).

Most BSI cases in this work were monomicrobial (98.9%), and the polymicrobial BSI was caused by *S. viridians*, CoNS, *Klebsiella* spp., *Acinetobacter*, *Candida* spp., *Enterobacter* spp. and *S. marcescens*. Polymicrobial bacteremia was reported in 5.2% in a previous study by Al-Zamil (2008). The causative agents involved in the polymicrobial bacteremia included *E. coli*, *P. aeruginosa*, *K. pneumoniae*, *K. oxytoca*, *S. marcescens*, *E. cloacae* and *A. baumannii* (Emori and Gaynes, 1993).

Many studies were in accordance to our results as Gram-positive bacteria were more prevalent than Gram-negatives (Karchmer, 2000; Gray, 2004; Hadziyannis et al., 2004; Babay et al., 2005; NCCLS, 2005; Asghar, 2006; Babay, 2007). Furthermore, Wisplinghoff et al. (2003) detected Gram-positive, Gram-negative and yeast in 65%, 24% and 11% of isolates in the US prospective surveillance for nosocomial BSI in pediatric patients at 49 hospitals during a 6-year period. On the other hand, some studies performed (Al-Orainey et al., 1989; Elbasher et al., 1998; Pourakbari et al., 2012) revealed a high occurrence of Gram-negative compared with Gram-positive bacteria.

Gram-positive cocci started reemerging as predominant pathogens in BSI in the early 1980s and it has been suggested that this change is due to evolution of medical care (Warran et al., 2001; Siefert and Wisplinghoff, 2005).

CoNS was the most frequent isolate in this study, which could be due to the increasing use of intravascular devices in the medical care of MMCH. It needs to be pointed out that *S. epidermidis* and other CoNS can cause sepsis particularly in preterm infants, immunosuppressed patients and patients with intravascular devices (Haimi-Cohen et al., 2002), where biofilm production plays a role in pathogenesis (Ninin et al., 2006). Furthermore, the increased isolation of CoNS in blood cultures; its association with higher mortality and prolongation of the length of hospital stay may reflect a change from regarding these organisms as normal skin flora to viewing them as clinically significant (Martin et al., 1989; Ahmed et al., 2009).

CoNS was the most common isolate overall accounting for 43% of the total isolates in study of Wisplinghoff et al. (2003). Recently, Ballot et al. (2012) reported the most common isolate overall was CoNS accounting for 19.1% of the total isolates, while, Saied et al. (2011)

265 reported CoNS as the second most frequent isolate accounting for 25.5% of the total
 266 isolates recovered from nosocomial BSI, only exceeded by *K. pneumonia* (26.7%).

267 The second most causative agents after CoNS in the cases under study were *Streptococcus*
 268 spp., of whom (1.7%) were *S. pneumonia*, which was also previously reported (Haddon et
 269 al., 1999). Al-Zamil (2008) reported that the most common Gram-positive isolates from
 270 pediatric BSI were *S. aureus* (18.7%) and *Streptococcus* spp. (16.3%).

271 The proportion of blood culture isolates of MRSA from children is increasing (Khairulddin et
 272 al., 2004). Furthermore, Bacteraemia due to MRSA is associated with high mortality
 273 compared with methicillin sensitive *S. aureus* bacteraemia (Ahmed et al., 2009).

274 Worldwide, MRSA rates vary widely, from <1% in Denmark, Sweden, and The Netherlands
 275 to >40% in the United Kingdom, Greece, and Italy (Tiemersma et al., 2004). In our study, we
 276 encountered 31/58 (53.45%) isolates of MRSA of the total *Staph. aureus* isolates, with the
 277 highest proportion in NICU (22/31, 71%). MRSA infections in MMCH was higher than
 278 reported by Gray (2004) which was 15.5%, and that reported by Khairulddin et al. (2004)
 279 (13.1%); but lower than a study from USA by Wisplinghoff et al. (2003) (29%) & a study from
 280 Egypt by Saied et al. (2011) (64%).

281 Increasing MRSA infection rates have been reported in tertiary care centers in Saudi Arabia
 282 between 2000 and 2004 (Balkhy et al., 2007). 5.9% of the Gram-positive bacteria recovered
 283 from blood cultures were MRSA. This is opposed to much higher rate reported from Iran,
 284 79% by Pourakbari et al. (2012). Promoting hand hygiene and isolation precautions are
 285 important measures to prevent the spread of MRSA.

286 No vancomycin-resistance was detected among *Enterococcus* isolates. However,
 287 Wisplinghoff et al. (2003) saw vancomycin-resistance in 1% of *Enterococcus faecalis* and in
 288 11% of *Enterococcus faecium* isolates.

289 BSI with gram-negative bacteria are one of the most serious infections in the hospital
 290 setting, a situation compounded by the increasing antibiotic resistance of gram-negative
 291 bacteria causing BSI (Sostarich et al., 2008). The most frequently isolated Gram-negative
 292 bacteria were *S. marcescens*. (62 isolate, 23.7%), which is a well-recognised cause of
 293 outbreaks of hospital-acquired infections, particularly in NICUs (Madani et al., 2011).

294 *P. aeruginosa* rate was 3.9% in this setting, which is in agreement with the 3.5% reported by
 295 Al-Zamil (2008). *P. aeruginosa* BSI in immunocompromised patients can lead to death within
 296 the first 72 hours (Munson et al., 2003). On contrary to our results, Wendt et al. (1998) and
 297 Weinstein et al. (1995) reported *P. aeruginosa* as the commonest Gram-negative pathogen
 298 isolated from BSI cases.

299 The incidence of BSI caused by *K. pneumoniae* in this investigation was 5.6%, which is
 300 comparable to that reported previously by Haddon et al. (1999) (7.4%); and Al-Zamil (2008)
 301 (6.6%).

302 *Candida* BSI contributes to increased length of hospital stay, increased hospital costs, and
 303 most importantly, increased morbidity and mortality (Garey et al., 2006). *Candida* spp. was
 304 implicated in 4.6% of all BSI episodes representing the fifth most common etiologic agent in
 305 this study. Previous studies indicated that *Candida* spp. represent the fourth to seventh most
 306 common etiologic agent causing septicemia (Rangel-Frausto et al., 1999, Lark et al., 2000,
 307 Hadziyannis et al., 2004). However, the infections with *Candida* spp. in our study was more

308 than what had been reported by Babay et al. (2005) and Saied et al. (2011) but less than
309 that of Gomaa et al. (2001).

310 The three departments generating the greatest number of microbial isolates in MMCH were
311 NICU, OPD and PICU. Our results confirmed that ICU is the most important department
312 generating the greatest number of positive cultures, which is quietly normal, since most of
313 the patients in the ICU are the critically ill or immunocompromised patients requiring
314 mechanical support and indwelling devices (Unal et al., 2004).

315 Increases in neonatal septicemia have been linked to increased use of prosthetic devices in
316 hospitals in recent years (Brodie et al., 2000); or to better methods of detection of organisms
317 in blood with more sensitive equipment such as the Bactec 9240 instrument (Gomaa et al.,
318 2001), that was used in the present study. The Bactec 9240 instrument facilitates the early
319 detection of microorganisms from blood cultures of newborn infants when compared with
320 other blood culture methods (Garcia-Prats et al., 2000).

321 Periodic testing and analysis of antibiotic resistance would enable physicians to detect
322 trends in the resistance pattern to commonly prescribed antibiotics in a given organism.

323 Gram-positive bacterial isolates showed a very low level of resistance to cephalothin and
324 vancomycin. Babay et al. (2005) reported none of the Gram-positive bacteria were resistant
325 to vancomycin. Our results also showed resistance of a large proportion of Gram-positives to
326 penicillin G (90.4%) and ampicillin (73.1%). In a study of Al-Zamil (2008), 95% of *S. aureus*
327 and 38% of *S. pneumoniae* was resistant to penicillin G.

328 An important observation was noted which is the high resistance pattern of *S. maltophilia* &
329 *C. meningosepticum* isolates to most antibiotics used. Treatment of *S. maltophilia* is
330 problematic owing to its high level of intrinsic resistance to multiple classes of antibiotics
331 (Vartivarian et al., 1994). A number of factors, including multidrug efflux pumps and outer
332 membrane impermeability, likely contribute to the intrinsic antibiotic resistance of *S.*
333 *maltophilia* (Cullmann, 1991; Alonso and Martinez, 2000).

334 *C. meningosepticum*, exists in water systems and wet surfaces of the hospital environment
335 (Hoque et al., 2001). *C. meningosepticum* is also resistant to multiple antibiotics (Arvanitidou
336 et al., 2003).

337 All our *C. albicans* isolated were susceptible to amphotericin B and fluconazole as Babay et
338 al. (2005), also reported the sensitivity of all fungal isolates to all antifungal agents tested.

339 The high resistance rates for the commonly used antibiotics in this study could be explained
340 by the fact that resistance develops wherever antibiotics are abused, overused, misused and
341 dispensed at levels lower than the suggested treatment guidelines. This means that
342 antibiotics kill only the non-resistant organisms, while leaving behind their tougher
343 counterparts to replicate and spread resistance genes.

344 Resistance to β -lactams, especially third-generation cephalosporins and non β -lactams,
345 among clinical isolates of Gram-negative bacteria is increasing worldwide (Andrews, 2001;
346 Quirante et al., 2011). The Gram-negative isolates among the studied patients demonstrated
347 a high level of resistance towards cefpodoxime (41.4%), cefotaxime (30%), ceftriaxone
348 (40.2%) and aztreonam (34.8%). This type of resistance is a marker for the presence of
349 extended-spectrum β -lactamases (ESBL) (Nathisuwan et al., 2001). Thus, phenotypic
350 screening of beta-lactamases should be performed; and *bla* genes identified.

351
352
353
354

355 4. CONCLUSION

356 BSIs are a major cause of morbidity and mortality in pediatrics. The pathogen distribution
357 was different from those in the developed countries with a predominance of CoNS,
358 *Streptococcus* spp. and *Serratia marcescens*. The incidence rate of BSI is high in ICUs
359 (PICU & NICU). So, special attention should be given to the quality of care for those patients
360 to improve safety. This could be done through training, proper selection of catheters and
361 sites, standardization of central venous catheter insertion and maintenance processes and
362 use prophylactic antimicrobial lock solution in patients who have a history of multiple
363 catheter-related BSI. Furthermore, empowerment of team members to enforce adherence to
364 best practices will help prevent and control hospital acquired infection.

365 There was appreciable resistance to commonly used antibiotics. Physicians should receive
366 regularly updated antibiograms to be familiar with trends for the antimicrobial agents used
367 frequently in their hospitals. It is also very important to define the potential of resistant
368 organisms colonization surveillance in all ICU patients to predict etiology of subsequent
369 infection and improve adequacy of empiric antimicrobial treatment.

370 Competing interests

371 AUTHORS HAVE DECLARED THAT NO COMPETING INTERESTS EXIST.

372 373 ETHICAL APPROVAL

374 Ethical Committee of the Madinah Maternity and Children's Hospital & the Scientific
375 Committee of Taibah University approved the study.

376 377 REFERENCES

- 378 Abou Elella, R., Najm, H.K., Balkhy, H., Bullard, L., Kabbani, M.S. (2010). Impact of
379 bloodstream infection on the outcome of children undergoing cardiac surgery.
380 *Pediatr Cardiol.*, 31(4), 483-489.
- 381 Ahmed, S.H., Daef, E.A., Badary, M.S., Mahmoud, M.A., Abd-Elsayed, A.A. (2009).
382 Nosocomial bloodstream infection in intensive care units at Assiut University
383 Hospitals (upper Egypt) with special reference to extended-spectrum β -
384 lactamase producing organisms. *BMC. Res. Notes*, 2, 76.
- 385 Alonso, A., and Martinez. J. L. (2000). Cloning and characterization of SmeDEF, a novel
386 multidrug efflux pump from *Stenotrophomonas maltophilia*. *Antimicrob. Agents*
387 *Chemother.*, 44, 3079–3086.
- 388 Al-Orainey, I., Al-Nasser, M., Saeed, E., Chowdhury, M. (1989). Nosocomial bacteremia in a
389 teaching hospital in Saudi Arabia. *J. Hosp. Infect.*, 14(3), 201-207.
- 390 Al-Zamil, F.A. (2008). Bacteremia in children at the university hospital in Riyadh, Saudi
391 Arabia. *World. J. Pediatr.*, 4(2), 118-22.

- 392 Andrews, J.M. (2001). BSAC standardized disk susceptibility testing method. J. Antimicrob.
393 Chemother., 48(1), 43-57.
- 394 Arvanitidou, M., Vayona, A., Spanakis, N., Tsakris, A. (2003), Occurrence and antimicrobial
395 resistance of Gram-negative bacteria isolated in haemodialysis water and
396 dialysate of renal units: results of a Greek multicentre study. J. Appl.Microbiol.,
397 95, 180–185.
- 398 Asghar, A.H. (2006). Frequency and antimicrobial susceptibility patterns of bacterial
399 pathogens isolated from septicemic patients in Makkah hospitals. Saudi. Med.
400 J., 27(3), 361-367.
- 401 Babay, H.A. (2007). Bacterial isolates from fatal cases of bloodstream infections at a
402 university hospital in central, Saudi Arabia. Saudi. Med. J., 28(2), 231-235.
- 403 Babay, H.A., Twum-Danso, K., Kambal, A.M., Al-Otaibi, F.E. (2005). Bloodstream infections
404 in pediatric patients. Saudi. Med. J., 26(10), 1555-1561.
- 405 Balkhy, H.H., Memish, Z.A., Almuneef, M.A., Cunningham, G.C., Francis, C., Fong, K.C.
406 (2007). Methicillin-resistant *Staphylococcus aureus*: a 5-year review of
407 surveillance data in a tertiary care hospital in Saudi Arabia. Infect. Control.
408 Hosp. Epidemiol., 28, 976-982.
- 409 Ballot, D.E., Nana, T., Sriruttan, C., Cooper, P.A. (2012). Bacterial Bloodstream Infections in
410 Neonates in a Developing Country, ISRN Pediatrics, Article ID 508512, 6
411 pages, doi:10.5402/2012/508512.
- 412 Biedenbach, D.J., Moet, G.J., Jones, R.N. (2004). Occurrence and antimicrobial resistance
413 pattern comparisons among bloodstream infection isolates from the SENTRY
414 antimicrobial surveillance program (1997-2002). Diagn. Microbiol. Infect. Dis.,
415 50(1), 59-69.
- 416 Blomberg, B., Manji, K.P., Urassa, W.K., Tamim, B.S., Mwakagile, D.S., Jureen, R., Msangi,
417 V., Tellevik, M.G., Holberg-Petersen, M., Harthug, S., Maselle, S.Y., Langeland,
418 N. (2007). Antimicrobial resistance predicts death in Tanzanian children with
419 bloodstream infections: a prospective cohort study. BMC. Infect. Dis., 7, 43.
- 420 Brodie, S.B., Sands, K.E., Gray, J.E., Parker, R.A., Goldmann, D.A., Davis, R.B.,
421 Richardson, D.K. (2000). Occurrence of nosocomial bloodstream infections in
422 six neonatal intensive care units. Pediatr. Infect. Dis. J., 19(1), 56-65.
- 423 Cullmann, W. (1991). Antibiotic susceptibility and outer membrane proteins of clinical
424 *Xanthomonas maltophilia* isolates. Chemotherapy, 37, 246–250.
- 425 Elbashier, A.M., Malik, A.G., Khot, A.P. (1998). Bloodstream infections: micro-organisms,
426 risk factors and mortality rate in Qatif central hospital. Ann. Saudi. Med., 18(2),
427 176-180.
- 428 Emori, T.G., Gaynes, R.P. (1993). An overview of nosocomial infections, including the role of
429 the microbiology laboratory. Clin. Microbiol. Rev. 6(4), 428-442.

430

- 431 Garcia-Prats, J.A., Cooper, T.R., Schneider, V.F., Stager, C.E., Hansen, T.N. (2000). Rapid
432 detection of microorganisms in blood cultures of newborn infants utilizing
433 automated blood culture system. *Pediatr.*, 105(3), 523-527.
- 434 Garey, K.W., Rege, M., Pai, M.P., Mingo, D.E., Suda, K.J., Turpin, R.S., Bearden, D.T.
435 (2006). Time to initiation of fluconazole therapy impacts mortality in patients
436 with candidemia: a multiinstitutional study. *Clin. Infect. Dis.*, 43(1), 25-31.
- 437 Gomaa, H.H.A., Udoc, E.E., Rajaram, U. (2001). Neonatal septicemia in Al-Jahra hospital,
438 Kuwait: etiologic agents and antibiotic sensitivity patterns. *Med. Princ. Pract.*,
439 10(3), 145-150.
- 440 Gray, J.W. (2004). A 7-year study of bloodstream infections in an English children's hospital.
441 *Eur. J. Pediatr.*, 163(9), 530-535.
- 442 Haddon, R.A., Barnett, P.L., Grimwood, K., Hogg, G.G. (1999). Bacteremia in febrile children
443 presenting to a pediatric emergency department. *Med. J. Aust.*, 170(10), 475-
444 478.
- 445 Hadziyannis, A., Stephanou, I., Dimarogona, K., Pantazatou, A., Fourkas, D., Filiagouridis,
446 D., Avlami, A. (2004). Blood culture results during the period 1995-2002 in a
447 Greek tertiary care hospital. *Clin. Microbiol. Infect.*, 10(7), 667-670.
- 448 Haimi-Cohen, Y., Vellozzi, E.M., Rubin, L.G. (2002). Initial concentration of *Staphylococcus*
449 *epidermidis* in simulated pediatric blood cultures correlates with time to positive
450 results with the automated, continuously monitored BACTEC blood culture
451 system. *J. Clin. Microbiol.*, 40(3), 898-901.
- 452 Haque, K.N., Chagia, A.H., Shaheed, M.M. (1990). Half a decade of neonatal sepsis,
453 Riyadh, Saudi Arabia. *J. Trop. Pediatr.*, 36(1), 20-23.
- 454 Hoque, S.N., Graham, J., Kaufmann, M.E., Tabaqchaki, S. (2001) *Chryseobacterium*
455 *(Flavobacterium) meningosepticum* outbreak associated with colonization of
456 water taps in a neonatal intensive care unit. *J. Hosp. Infect.*, 47, 188-192.
- 457 Jain, A., Roy, I., Gupta, M.K., Kumar, M., Agarwal, S.K. (2003). Prevalence of extended-
458 spectrum β -lactamase-producing Gram-negative bacteria in septicemic
459 neonates in a tertiary care hospital. *J. Med. Microbiol.*, 52(5), 421-425.
- 460 Karchmer, A. (2000). Nosocomial bloodstream infections: organisms, risk factors, and
461 implications. *Clin. Infect. Dis.*, 31(4), 139-143.
- 462 Khairulddin, N., Bishop, L., Lamagni, T.L., Sharland, M., Duckworth, G. (2004). Emergence
463 of methicillin-resistant *Staphylococcus aureus* (MRSA) bacteraemia among
464 children in England and Wales, 1990-2001. *Arch. Dis. Child.*, 89(4), 378-379.
- 465 Lark, R., Chenoweth, C., Saint, S., Zemencuk, J., Lipsky, B., Plorde, J. (2000). Four year
466 prospective evaluation of nosocomial bacteremia: epidemiology, microbiology,
467 and patient outcome. *Diagn. Microbiol. Infect. Dis.*, 38(3), 131-140.

- 468 Laupland, K.B., Gregson, D.B., Vanderkooi, O.G., Ross, T., Kellner, J.D. (2009). The
469 changing burden of pediatric bloodstream infections in Calgary, Canada, 2000-
470 2006. *Pediatr. Infect. Dis. J.*, 28 (2), 114-117.
- 471 Liu, C.Y., Liao, C.H., Chen, Y.C., Chang, S.C. (2010). Changing epidemiology of nosocomial
472 bloodstream infections in 11 teaching hospitals in Taiwan between 1993 and
473 2006. *J. Microbiol. Immunol. Infect.*, 43(5), 416-429.
- 474 Madani, T.A., Alsaedi, S., James, L., Eldeek, B.S., Jiman-Fatani, A.A., Alawi, M.M., Marwan,
475 D., Cudal, M., Macapagal, M., Bahlas, R., Farouq, M. (2011). *Serratia*
476 *marcescens*-contaminated baby shampoo causing an outbreak among
477 newborns at King Abdulaziz University Hospital, Jeddah, Saudi Arabia. *J. Hosp.*
478 *Infect.*, 78(1), 16-19.
- 479 Mahapatra, A., Ghosh, S.K., Mishra, S., Pattnaik, D., Pattnaik, K., Mohanty, S.K. (2002).
480 *Enterobacter cloacae*: A predominant pathogen in neonatal septicaemia. *Indian*.
481 *J. Med. Microbiol.*, 20(2), 110-112.
- 482 Mahfouz, A.A., Al-Azraqi, T.A., Abbag, F.I., Al-Gamal, M.N., Seef, S., Bello, C.S. (2010).
483 Nosocomial infections in a neonatal intensive care unit in South-Western Saudi
484 Arabia. *East. Mediterr. Health. J.*, 16(1), 40-44.
- 485 Martin, M.A., Pfaller, M.A., Wenzel, R.P. (1989). Coagulase-negative staphylococcal
486 bacteremia. Mortality and hospital stay. *Ann. Intern. Med.*, 110(1), 9-16.
- 487 McLaughlin, G.E., Nares, M.A., Smith, L.J., Feinroth, C. A. (2012). Preventing central-line-
488 associated bloodstream infections in pediatric specialized care units: A case
489 study of successful quality improvement. *Prog. Pediatr. Cardiol.*, 33, 47–52.
- 490 Meyer, E., Beyersmann, J., Bertz, H., Wenzler-Röttele, S., Babikir, R., Schumacher, M.,
491 Daschner, F.D., Rüden, H., Dettenkofer, M., ONKO-KISS Study Group. (2007).
492 Risk factor analysis of blood stream infection and pneumonia in neutropenic
493 patients after peripheral blood stem-cell transplantation. *Bone Marrow*
494 *Transplant*, 39(3), 173-178.
- 495 Munson, E.L., Diekema, D.J., Beekmann, S.E., Chapin, K.C., Doern, G.V. (2003). Detection
496 and treatment of bloodstream infection: laboratory reporting and antimicrobial
497 management. *J. Clin. Microbiol.*, 41, 495-497.
- 498 Nathisuwan, S., Burgess, D.S., Lewis II, J.S. (2001). Extended-spectrum β -lactamases:
499 epidemiology, detection, and treatment. *Pharmacother.*, 21(8), 920-928.
- 500 National Committee for Clinical Laboratory Standards (2005). Performance standards for
501 antimicrobial susceptibility testing. 15th informational supplement. Document
502 M100-S15. Wayne, Pennsylvania: NCCLS.
- 503 Ninin, E., Caroff, N., Espaze, E., Maraillac, J., Lepelletier, D., Milpied, N., Richet, H. (2006).
504 Assessment of *ica* operon carriage and biofilm production in *Staphylococcus*
505 *epidermidis* isolates causing bacteraemia in bone marrow transplant recipients.
506 *Clin. Microbiol. Infect.*, 12(5), 446-452.

- 507 Pourakbari, B., Sadr, A., Ashtiani, M.T., Mamishi, S., Dehghani, M., Mahmoudi, S., Salavati,
508 A., Asgari, F. (2012). Five-year evaluation of the antimicrobial susceptibility
509 patterns of bacteria causing bloodstream infections in Iran. *J. Infect. Dev.*
510 *Ctries.*, 6(2), 120-125.
- 511 Quirante, O.F., Cerrato, S.G., Pardos, S.L. (2011). Risk factors for bloodstream infections
512 caused by extended-spectrum β -lactamase-producing *Escherichia coli* and
513 *Klebsiella pneumoniae*. *Braz. J. Infect. Dis.*, 15(4), 370-376.
- 514 Rangel-Frausto, M.S., Wiblin, T., Blumberg, H.M., Saiman, L., Patterson, J., Rinaldi, M.,
515 Pfaller, M., Edwards, JE Jr., Jarvis, W., Dawson, J., Wenzel, R.P. (1999).
516 National epidemiology of mycoses survey (NEMIS): variations in rates of
517 bloodstream infections due to *Candida* species in seven surgical intensive care
518 units and six neonatal intensive care units. *Clin. Infect. Dis.*, 29, 253-258.
- 519 Rosenthal, V.D., Guzman, S., Migone, O., Crnich, C.J. (2003). The attributable cost of
520 hospital stay, and mortality of central line associated bloodstream infections in
521 intensive care departments in Argentina: a prospective analysis. *Am. J. Infect.*
522 *Control*, 31(8), 475-480.
- 523 Saied, T., Elkholy, A., Hafez, S.F., Basim, H., Wasfy, M.O., El-Shoubary, W., Samir A;
524 Pimentel, G., Talaat, M. (2011). Antimicrobial resistance in pathogens causing
525 nosocomial bloodstream infections in university hospitals in Egypt. *Am. J.*
526 *Infect. Control*, 39, 61-5.
- 527 Sherry L. M., Jiaquan, Xu., Kenneth D. K. (2012). Deaths: Preliminary Data for 2010.
528 National Vital Statistics Reports. Volume 60, Number 4. National Center for
529 Health Statistics 2012. Available from
530 http://www.cdc.gov/nchs/data/nvsr/nvsr60/nvsr60_04.pdf.
- 531 Siefert, H., Wisplinghoff, H. (2005). Bloodstream infection and endocarditis. In: Borriello,
532 S.P.; Murray, P.R.; Funke, G. (eds.). Topley and Wilson's microbiology and
533 microbial infections. Vol 1. 10th Ed. London: Edward Arnold: pp. 509-526.
- 534 Sostarich, A.M., Zolldann, D., Haefner, H., Luetticken, R., Schulze-Roebecke, R., Lemmen,
535 S.W. (2008). Impact of multiresistance of gram-negative bacteria in
536 bloodstream infection on mortality rates and length of stay. *Infect.*, 36(1), 31-
537 35.
- 538 Tiemersma, E.W., Bronzwaer, S.L., Lyytikainen, O., Degener, J.E., Schrijnemakers, P.,
539 Bruinsma, N., Monen, J., Witte, W., Grundman, H. (2004). Methicillin-resistant
540 *Staphylococcus aureus* in Europe, 1999-2002. *Emerg. Infect. Dis.*, 10, 1627-
541 1634.
- 542 Unal, S., Masterton, R., Goossens, H. (2004). Bacteremia in Europe antimicrobial
543 susceptibility data from the MYSTIC surveillance program. *Int. J. Antimicrob.*
544 *Agents*, 23(2), 155-163.
- 545 Vartivarian, S., Anaissie, E., Bodey, G., Sprigg, H., Rolston, K. (1994). A changing pattern of
546 susceptibility of *Xanthomonas maltophilia* to antimicrobial agents: implications
547 for therapy. *Antimicrob. Agents Chemother.*, 38, 624-627.

- 548 Warran, D., Zack, J., Elward, A., Cox, M., Fraser, V. (2001). Nosocomial primary
549 bloodstream infections in intensive care unit patients in a non teaching
550 community medical center: a 21-month prospective study. Clin. Infect. Dis.,
551 33(8), 1329-1335.
- 552 Weinstein, M.P., Mirrett, S., Reimer, L.G., Wilson, M.L., Smith- Elekes, S., Chuard, C.R.,
553 Joho, K.L., Reller, L.B. (1995). Controlled evaluation of BacT/Alert standard
554 aerobic and FAN aerobic blood culture bottles for detection of bacteremia and
555 fungemia. J. Clin. Microbiol. 33(4), 978-981.
- 556 Wendt, C., Messer, S.A., Hollis, R.J., Pfaller, M.A., Herwaldt, L.A. (1998). Epidemiology of
557 polyclonal Gram-negative bacteremia. Diagn. Microbiol. Infect. Dis. 32(1), 9-13.
- 558 Wisplinghoff, H., Seifert, H., Tallent, S.M., Bischoff, T., Wenzel, R., Edmond, M.B.
559 (2003). Nosocomial bloodstream infections in pediatric patients in United States
560 hospitals: epidemiology, clinical features and susceptibilities. Pediatr. Infect.
561 Dis. J., 22(8), 686-691.
- 562 Yogaraj, J.S., Elward, A.M., Fraser, V.J. (2002). Rate, risk factors and outcomes of
563 nosocomial primary bloodstream infection in pediatric intensive care unit
564 patients. Pediatr., 110(3), 481-485.